REBECCA Real-world Early BrEast CanCer mAnagement
REBECCA
1 other identifier
observational
126
1 country
58
Brief Summary
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2024
Typical duration for all trials
58 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 12, 2024
CompletedStudy Start
First participant enrolled
December 30, 2024
CompletedFirst Posted
Study publicly available on registry
March 4, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 31, 2028
March 25, 2026
March 1, 2026
3.1 years
December 12, 2024
March 24, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Proportion of patients who receive Olaparib for the full treatment duration
The primary outcome is the evaluation of the proportion of patients who receive Olaparib for the full treatment duration, described as 12 months of treatment.
18 months after inclusion
Secondary Outcomes (4)
BRCA characteristics: Mutation type
18 months after inclusion
Type of variants
18 months after inclusion
Medical history
18 months after inclusion
Time to Olaparib treatment discontinuation
18 months after inclusion
Eligibility Criteria
Patients will be recruited from about 60 participating sites to reach the target of 126 subjects, with a maximum of 60% of subtype TN overall.
You may qualify if:
- Male or female aged ≥ 18 years
- Patient diagnosed with HER2-negative eBC
- Patient about to be initiated with adjuvant Olaparib at their physician's discretion
- Patient has been informed and does not object to participation in the study.
You may not qualify if:
- Patient not consenting to participate.
- Patients included in the Early Access Program
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (58)
Research Site
Clermont-Ferrand, Auvergne-Rh ne-Alpes, 63050, France
Research Site
Gleizé, Auvergne-Rh ne-Alpes, 69400, France
Research Site
Grenoble, Auvergne-Rh ne-Alpes, 38000, France
Research Site
Lyon, Auvergne-Rh ne-Alpes, 69317, France
Research Site
Metz-Tessy, Auvergne-Rh ne-Alpes, 74370, France
Research Site
Saint-Etienne, Auvergne-Rh ne-Alpes, 42030, France
Research Site
Saint-Priest-en-Jarez, Auvergne-Rh ne-Alpes, 42271, France
Research Site
Thonon-les-Bains, Auvergne-Rh ne-Alpes, 74200, France
Research Site
Valence, Auvergne-Rh ne-Alpes, 26000, France
Research Site
Valence, Auvergne-Rh ne-Alpes, 26953, France
Research Site
Dijon, Bourgogne-Franche-Comt, 21079, France
Research Site
Plérin, Brittany Region, 22190, France
Research Site
Rennes, Brittany Region, 35042, France
Research Site
Saint-Brieuc, Brittany Region, 22027, France
Research Site
Saint-Grégoire, Brittany Region, 35768, France
Research Site
Chambray-lès-Tours, Centre-Val de Loire, 37170, France
Research Site
Saint-Doulchard, Centre-Val de Loire, 18230, France
Research Site
Bezannes, Grand Est, 51430, France
Research Site
Haguenau, Grand Est, 67504, France
Research Site
Nancy, Grand Est, 54100, France
Research Site
Beauvais, Hauts-de-France, 60021, France
Research Site
Beuvry, Hauts-de-France, 62660, France
Research Site
Compiègne, Hauts-de-France, 60204, France
Research Site
Creil, Hauts-de-France, 60109, France
Research Site
Dechy, Hauts-de-France, 59187, France
Research Site
Lille, Hauts-de-France, 59020, France
Research Site
Lille, Hauts-de-France, 59037, France
Research Site
Saint-Martin-Boulogne, Hauts-de-France, 62280, France
Research Site
Salouël, Hauts-de-France, 80054, France
Research Site
Saint-Pierre-des-Corps, La R Union, 97448, France
Research Site
FORT de France Cedex, Martinique, 97261, France
Research Site
Caen, Normandy, 14000, France
Research Site
Rouen, Normandy, 76175, France
Research Site
Agen, Nouvelle-Aquitaine, 47923, France
Research Site
Libourne, Nouvelle-Aquitaine, 33505, France
Research Site
Limoges, Nouvelle-Aquitaine, 87042, France
Research Site
Périgueux, Nouvelle-Aquitaine, 24000, France
Research Site
Poitiers, Nouvelle-Aquitaine, 86021, France
Research Site
Béziers, Occitanie, 34500, France
Research Site
Montpellier, Occitanie, 34070, France
Research Site
Montpellier, Occitanie, 34298, France
Research Site
Nîmes, Occitanie, 30900, France
Research Site
Perpignan, Occitanie, 66046, France
Research Site
Toulouse, Occitanie, 31300, France
Research Site
Nantes, Pays de la Loire Region, 44202, France
Research Site
Avignon, Provence-Alpes-C Te d'Azur, 84918, France
Research Site
Fréjus, Provence-Alpes-C Te d'Azur, 83608, France
Research Site
Marseille, Provence-Alpes-C Te d'Azur, 13385, France
Research Site
Nice, Provence-Alpes-C Te d'Azur, 06105, France
Research Site
Argenteuil, Île-de-France Region, 95107, France
Research Site
Champigny-sur-Marne, Île-de-France Region, 94507, France
Research Site
Le Blanc-Mesnil, Île-de-France Region, 93150, France
Research Site
Osny, Île-de-France Region, 95520, France
Research Site
Paris, Île-de-France Region, 75651, France
Research Site
Paris, Île-de-France Region, 75674, France
Research Site
Paris, Île-de-France Region, 75908, France
Research Site
Paris, Île-de-France Region, 75970, France
Research Site
Sarcelles, Île-de-France Region, 95200, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
AstraZeneca Clinical Study Information Center
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 12, 2024
First Posted
March 4, 2025
Study Start
December 30, 2024
Primary Completion (Estimated)
January 31, 2028
Study Completion (Estimated)
January 31, 2028
Last Updated
March 25, 2026
Record last verified: 2026-03